23andme Holding Co (ME)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
23andMe Announces Promising Immuno-Oncology Programs at AACR Annual Meeting 2024
23andMe Holding Co.*s Deficit Swells in Q4 2023, Revenue Plunges by Over a Third
Redemption of Diminishing Returns at ME amid the fourth quarter of 2023 earnings season
Observing the first quarter of 2022 performance, the company*s reported a solid Top-line increase